Reliv’ International (OTCMKTS:RELV – Get Free Report) and AEON Biopharma (NASDAQ:AEON – Get Free Report) are both small-cap consumer staples companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, valuation, profitability and analyst recommendations.
Volatility & Risk
Reliv’ International has a beta of -0.04, meaning that its stock price is 104% less volatile than the S&P 500. Comparatively, AEON Biopharma has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500.
Earnings & Valuation
This table compares Reliv’ International and AEON Biopharma”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Reliv’ International | $35.06 million | 0.10 | -$440,000.00 | ($0.09) | -22.22 |
| AEON Biopharma | N/A | N/A | -$36.63 million | ($5.00) | -0.06 |
Reliv’ International has higher revenue and earnings than AEON Biopharma. Reliv’ International is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Reliv’ International and AEON Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Reliv’ International | -0.61% | -1.89% | -1.31% |
| AEON Biopharma | N/A | N/A | -994.63% |
Institutional & Insider Ownership
7.7% of Reliv’ International shares are owned by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are owned by institutional investors. 30.0% of Reliv’ International shares are owned by insiders. Comparatively, 9.4% of AEON Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of current ratings and target prices for Reliv’ International and AEON Biopharma, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Reliv’ International | 0 | 0 | 0 | 0 | 0.00 |
| AEON Biopharma | 0 | 1 | 1 | 1 | 3.00 |
Summary
AEON Biopharma beats Reliv’ International on 8 of the 13 factors compared between the two stocks.
About Reliv’ International
Reliv' International, Inc. develops and markets nutritional supplements that address basic nutrition, specific wellness needs, weight management, and sports nutrition. The company's basic nutritional supplements are formulated to provide a balanced and complete level of supplementation for the consumer. Its principal products include Reliv Classic, Reliv Now, Innergize!, and FibRestore along with LunaRich X capsules. The company markets and sells its products through a direct selling system of independent distributors in the United States, Australia, Austria, Canada, France, Germany, Indonesia, Ireland, Malaysia, Mexico, the Netherlands, New Zealand, the Philippines, and the United Kingdom. Reliv' International, Inc. was founded in 1988 and is headquartered in Chesterfield, Missouri.
About AEON Biopharma
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.
Receive News & Ratings for Reliv' International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reliv' International and related companies with MarketBeat.com's FREE daily email newsletter.
